Orforglipron is a non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist, developed for the treatment of type 2
diabetes and obesity. As one of the most closely watched oral GLP-1 candidates in clinical development, it has drawn significant
interest across the pharmaceutical research community.
As a dedicated supplier of pharmaceutical intermediates and APIs, EOS Med CDMO offers Orogelipron for research and development use, We support scale-up production up to kilogram levels and provide full Drug Master File (DMF) documentation support. Every shipment comes with complete technical dossiers, including COA, MSDS, and analytical data (HPLC/HNMR), to ensure seamless regulatory compliance for your project.
Supply Capability
stock: In stock
Batch size: gram to multi-kilogram
Purity: 98%+ (HPLC)
Production: GMP-compliant facility
Specifications
CAS Number: 2212020-52-3
Target: GLP-1 receptor agonist (non-peptide, oral)
Research Area: Type 2 diabetes / Obesity / Metabolic disease
Transportation Conditions: This product is a non-hazardous chemical and should be transported at room temperature. It can be stably stored for several weeks during normal transportation and customs clearance.
Storage Conditions: Short-term (days to weeks) storage at 0-4°C; long-term (months to years) storage at -20°C.
Solubility: To be determined.
Shelf Life: Over 2 years under proper storage conditions.
Pharmaceutical Preparations: To be determined.
Catalyst Storage: Short-term (days to weeks) storage at 0-4°C; long-term (months) storage at -20°C.
HS Code: 2934.99.9001